靶向双肿瘤相关抗原（tumor-associated antigen，TAA）的双抗ADC（bispecific ADC）具有多种潜在抗肿瘤优势：

1. 同时靶向双肿瘤驱动分子，克服耐药性；

2. 识别双TAA共表达的肿瘤细胞，增加靶向肿瘤特异性，降低脱靶毒性；

3. 双靶点组合产生新的内吞动力学机制，更高效的杀伤肿瘤；

4. 提高肿瘤的ADC富集和暴露，有助于更强和更长久的杀伤异质性肿瘤。

云顶国际新型双抗ADC平台优势

1. RenLite来源的共同轻链抗体易于构建双抗分子，且性质稳定易于后期开发，显著降低了CMC工艺开发难度
2. 靶点敲除（KO）小鼠免疫获得的抗体表位丰富，多物种交叉且物种间亲和力接近
3. 具有自主知识产权的Linker&Payload平台BLD1102
   
4. 候选靶点多，多物种检测药效和毒性，开发周期短成功率高

新型Linker & Payload平台BLD1102

云顶国际已开发出具有自主知识产权的新型ADC平台BLD1102。

1）该平台使用的payload是新型拓扑异构酶1抑制剂BCPT02，具有广谱、强效的肿瘤杀伤能力

2）独特设计的可裂解linker具有优异亲水特性，赋予ADC如单抗般的亲水性质，极大改善了ADC的理化性质

3）BLD1102具有高度的血浆稳定性及更强效的肿瘤杀伤，

4）在临床前非人灵长类动物安全性评价中展示出良好的耐受性，是优异的新一代ADC技术平台。

基于RenLite平台的双抗ADC构建

基于RenLite的云顶国际双抗ADC平台小视频

货架型TAA抗体骨架序列

20+在研双抗ADC，开放合作

海报下载

Festival of Biologics 2024: Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)

AACR 2024: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

AACR 2024: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

AACR 2024: A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

AACR 2024: BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

AACR 2024: A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model

AACR 2024: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

SITC 2023: *DM001, a novel TROP2xEGFR bsADC, demonstrates potent tumor growth inhibition in preclinical models and favorable safety profile in monkey

SITC 2023:Preclinical Evaluation of Fully Human Bispecific Antibody-drug Candidates Targeting HER3 and the Juxtamembrane Region of MUC1

SITC 2023: *DM005, an EGFR х MET bsADC with a novel DNA topoisomerase I inhibitor payload, showed robust anti-tumor activity in preclinical models

SITC 2023: BSA01, a bsADC targeting EGFR and membrane-bound MUC1-C, exhibits anti-tumor efficacy in vivo

SITC 2023: BCG022: A HER3×MET Bispecific Antibody-drug Conjugate (BsADC) Targeting Key Mechanisms of Bypass Resistance in Multiple Tumor Types

SITC 2023: A novel bsADC targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts

AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy 

AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy 

AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity 

AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET 

AACR2023：Discovery of BCG033, A Novel Anti-PTK7xTROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer 

AACR 2023: A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy

AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1

AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate 

IO Summit EU 2023: YH013, a Common Light Chain Bispecific ADC Targeting EGFR and MET, Improves Preclinical Efficacy Over Its Parental Single-Targeting ADCs 

AACR 2022：YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy  

World ADC San Diego2022：YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy 

PEGS EUROPE 2022：YH013, a fully-human EGFR x c-MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy 

相关新闻

云顶国际与ABL Bio达成合作，共同开发新型双抗ADC药物

云顶国际与Radiance Biopharma达成双抗ADC协议

网络研讨会

April 24, 2024 | Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload

July 19, 2023 | Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety